KSI-301: An antibody-biopolymer conjugate for extended durability in retinal diseases

Time: 12:30 pm
day: Day Two


  • Biophysical and biochemical principles of Kodiak Sciences’ antibody-biopolymer conjugate (ABC) platform
  • Leveraging precise engineering of ABCs to achieve improved clinical outcomes in wet AMD, DME, and retinal vein occlusion
  • An overview of preclinical and clinical studies to-date involving KSI-301, the first ABC for retinal diseases